MedTrace Logo

Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial

NCT04327349 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-03-31

No results posted yet for this study

Summary

Coronavirus disease 2019 (COVID-19) was recognized as a pandemic on March 11, 2020 by the World Health Organization. The virus that causes COVID-19 (SARS-CoV-2) is easily transmitted through person to person and there is still no specific approach against the disease and mortality rate in severe cases is also significant. Therefore, finding effective treatment for the mortality of these patients is very important. In this study the investigators aim to determine the effect of Convalescent Plasma on COVID-19 patients Outcome through a Clinical Trial

Conditions

  • Coronavirus Infections

Interventions

BIOLOGICAL

Convalescent Plasma

Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU

Sponsors & Collaborators

  • Mazandaran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Majid Saeedi, Ph.D. · Vice-Chancellor for Research, Mazandaran University of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-28
Primary Completion
2020-05-20
Completion
2020-09-30

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04327349 on ClinicalTrials.gov